These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24205723)

  • 1. [Metabolic syndrome and diabetes mellitus].
    Nihon Rinsho; 2013 Sep; 71(9):1611-7. PubMed ID: 24205723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridemia secondary to obesity and diabetes.
    Subramanian S; Chait A
    Biochim Biophys Acta; 2012 May; 1821(5):819-25. PubMed ID: 22005032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atherogenic dyslipidemia and the metabolic syndrome: pathophysiological mechanisms].
    Zák A; Slabý A
    Cas Lek Cesk; 2008; 147(9):459-70. PubMed ID: 18988488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia in the metabolic syndrome: clinical implications and management.
    Hafidh SA; Lavie CJ; Burns BP; Khan SS; Alpert MA
    Minerva Cardioangiol; 2006 Apr; 54(2):215-27. PubMed ID: 16778753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?
    Li N; Fu J; Koonen DP; Kuivenhoven JA; Snieder H; Hofker MH
    Atherosclerosis; 2014 Mar; 233(1):130-8. PubMed ID: 24529133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of triglycerides for other metabolic parameters in the familial metabolic syndrome].
    Metzler W; Fücker K; Schwanebeck U; Hanefeld M; Julius U; Kindel B; Fischer S
    Dtsch Med Wochenschr; 2003 Sep; 128(38):1941-6. PubMed ID: 14502445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathophysiology of NAsh/NAFLD associated with high levels of serum triglycerides].
    Ogawa Y; Imajo K; Yoneda M; Nakajima A
    Nihon Rinsho; 2013 Sep; 71(9):1623-9. PubMed ID: 24205725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease under the influence of excess visceral fat.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.
    Tenenbaum A; Klempfner R; Fisman EZ
    Cardiovasc Diabetol; 2014 Dec; 13():159. PubMed ID: 25471221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
    Malloy MJ; Kane JP
    Adv Intern Med; 2001; 47():111-36. PubMed ID: 11795072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertriglyceridemia is a practical biomarker of metabolic syndrome in individuals with abdominal obesity.
    Li Z; Deng ML; Tseng CH; Heber D
    Metab Syndr Relat Disord; 2013 Apr; 11(2):87-91. PubMed ID: 23259588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The metabolic syndrome and insulin resistance].
    Kotani K; Kaku K
    Nihon Rinsho; 2005 Aug; 63(8):1485-91. PubMed ID: 16101244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward an improved diagnosis of the metabolic syndrome other clues to the presence of insulin resistance.
    Cohn GS; Kittleson MM; Blumenthal RS
    Am J Hypertens; 2005 Aug; 18(8):1099-103. PubMed ID: 16109324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.